ProCE Banner Activity

ADAURA Trial Update: Adjuvant Osimertinib vs Placebo After Complete Resection in Stage IB-IIIA EGFR-Mutated NSCLC

Slideset Download
Conference Coverage
Updated results from the phase III ADAURA trial showed a clinically meaningful improvement in DFS with adjuvant osimertinib vs placebo in fully resected stage IB-IIIA EGFR-mutated NSCLC.

Released: September 19, 2022

Expiration: September 18, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp